Figure 1
In vitro anti-myeloma activity of PU-H71. (A) Drug-sensitive human myeloma cell lines were treated with PU-H71 for 24 hours followed by cell viability analysis. (B) Same as (A) except that drug-resistant cell lines are used. (C) Synergistic effects of PU-H71 (100 nM) with melphalan (1 μM), dexamethasone (1 μM), thalidomide (1 μM) and bortezomib (100 nM) on INA-6 cells treated for 24 hours. * p < 0.05